Shares of Nu Skin (NUS -8.7%) are getting hit today on a Citron Research report accusing the...
Tuesday, August 7, 2012, 2:02 PM ETShares of Nu Skin (NUS -8.7%) are getting hit today on a Citron Research report accusing the company of being in violation of "direct selling" rules in China, putting their entire Chinese business operation "in jeopardy of seizure." Citron notes that NUS' China business comprised almost 75% of its Y/Y revenue growth in Q2, making the risk of its China operations coming to an abrupt halt massive, and the consequences devastating. Herbalife (HLF -1.7%) and Usana Health Services (USNA -3.7%) also trade down on the report.
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles